Bris­tol My­ers and Janssen race to­ward PhI­II with a next-gen blood thin­ner

Bris­tol My­ers Squibb and J&J joined forces three years ago with a vi­sion: They want­ed to cre­ate a blood thin­ner with the ef­fi­ca­cy of their cur­rent drugs Eliquis and Xarel­to, but with­out the height­ened risk of bleed­ing.

On Mon­day, they an­nounced they’re well on their way with a Fac­tor XIa in­hibitor called mil­vex­i­an.

Mil­vex­i­an, al­so known as BMS-986177, sig­nif­i­cant­ly low­ered pa­tients’ rate of ve­nous throm­boem­bolism (VTE) af­ter knee surgery com­pared to the com­mon­ly used an­ti­co­ag­u­lant enoxa­parin in a Phase II study, the part­ners said at this year’s Amer­i­can Heart As­so­ci­a­tion con­fer­ence — and with­out in­creas­ing risk of bleed­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.